05:51 PM EDT, 08/06/2024 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) fell almost 13%, after reporting Q2 net income late Tuesday of $0.20 per diluted share compared with $0.01 a year earlier.

Analysts polled by Capital IQ expected $0.17.

Revenue for the quarter ended June 30 was $242 million, compared with $165.2 million a year earlier.

Analysts expected $235.7 million.

For 2024, the company is now projecting revenue of $930 million to $980 million compared with its prior forecast expecting between $930 million to $1.01 billion.

Analysts polled by Capital IQ are looking for $954.2 million.

Price: 16.45, Change: -2.40, Percent Change: -12.73